Compare JVA & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JVA | ALLR |
|---|---|---|
| Founded | 1971 | 2004 |
| Country | United States | United States |
| Employees | 92 | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.8M | 19.3M |
| IPO Year | 1997 | 2021 |
| Metric | JVA | ALLR |
|---|---|---|
| Price | $3.17 | $0.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.50 |
| AVG Volume (30 Days) | 61.9K | ★ 201.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 2.57% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $90,655,294.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.48 | ★ N/A |
| Revenue Growth | ★ 17.54 | N/A |
| 52 Week Low | $2.76 | $0.61 |
| 52 Week High | $9.93 | $2.35 |
| Indicator | JVA | ALLR |
|---|---|---|
| Relative Strength Index (RSI) | 45.30 | 47.37 |
| Support Level | $3.00 | $0.80 |
| Resistance Level | $4.38 | $0.96 |
| Average True Range (ATR) | 0.14 | 0.10 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 83.33 | 51.33 |
Coffee Holding Co Inc is engaged in wholesale coffee operations, including manufacturing, roasting, packaging, marketing, and distributing roasted and blended coffees for privately labeled accounts and its brands, and it sells green coffee. The Company also manufactures and sells coffee roasters. Its products include wholesale green coffee, private-label coffee, and branded coffee. The company sells its coffee products throughout the United States, Canada, and certain Asian countries. The group's services are Custom Blending, Food Service Programs, and Private Label Services.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.